

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

SECTION 1. IDENTIFICATION

Product name : Halofuginone Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Eye irritation : Category 2A

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H319 Causes serious eye irritation.

Precautionary Statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P280 Wear eye protection and face protection.
Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 If eye irritation persists: Get medical attention.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
 Date of first issue: 08/26/2016

Chemical name	CAS-No.	Concentration (% w/w)
Lactic acid	50-21-5	$\geq 1 - < 5$
Halofuginone	82186-71-8	< 0.1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.
 Remove contaminated clothing and shoes.
 Get medical attention.
 Wash clothing before reuse.
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
 If easy to do, remove contact lens, if worn.
 Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention if symptoms occur.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
 Use water spray to cool unopened containers.
 Remove undamaged containers from fire area if it is safe to do so.
 Evacuate area.
- Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
5.7	04/09/2022	845725-00017	Date of first issue: 08/26/2016

for fire-fighters

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing. Avoid inhalation of vapor or mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
 Date of first issue: 08/26/2016

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Halofuginone	82186-71-8	TWA	5 µg/m ³ (OEB 4)	Internal
Further information: DSEN, Skin				
		Wipe limit	50 µg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
5.7	04/09/2022	845725-00017	Date of first issue: 08/26/2016

When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	yellow
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	2.1 - 3
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

Halofuginone:

Acute oral toxicity : LD50 (Rat): 30 mg/kg
LD50 (Mouse): 5 mg/kg
Acute inhalation toxicity : LC50 (Rat): 0.053 mg/l
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): 16 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Lactic acid:**

Species : Rabbit
Result : Skin irritation
Remarks : Based on data from similar materials

Halofuginone:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Lactic acid:**

Species : Chicken eye
Remarks : Based on data from similar materials
Result : Irreversible effects on the eye

Halofuginone:

Result : Severe irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Lactic acid:**

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

Remarks : Based on data from similar materials

Halofuginone:

Routes of exposure : Dermal
Species : Guinea pig
Result : Sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Halofuginone:

Genotoxicity in vitro : Test Type: Ames test
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Test Type: Chromosomal aberration
Test system: human lymphoblastoid cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Test Type: Cytogenetic assay
Species: Rat
Application Route: Oral
Result: negative

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

Test Type: DNA Repair
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative
Remarks : Based on data from similar materials

Halofuginone:

Species : Mouse
Application Route : Oral
NOAEL : 0.24 mg/kg body weight
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 63 weeks
NOAEL : 0.36 mg/kg body weight
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 26 Months
NOAEL : 0.09 - 0.18 mg/kg body weight
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development
Species: Mouse
Application Route: Ingestion

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
5.7	04/09/2022	845725-00017	Date of first issue: 08/26/2016

Result: negative

Halofuginone:

Effects on fertility

: Test Type: Fertility
 Species: Mouse
 Application Route: Oral
 Fertility: NOAEL: 0.126 mg/kg body weight
 Result: No effects on fertility.

Test Type: Fertility
 Species: Dog
 Application Route: Oral
 Fertility: LOAEL: 0.067 mg/kg body weight
 Result: Effects on fertility.

Test Type: Three-generation reproduction toxicity study
 Species: Mouse
 Application Route: Oral
 General Toxicity F1: LOAEL: 0.063 mg/kg body weight
 Symptoms: Reduced body weight
 Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development

: Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 General Toxicity Maternal: LOAEL: 0.34 mg/kg body weight
 Embryo-fetal toxicity.: NOAEL: 0.67 mg/kg body weight
 Result: No embryo-fetal toxicity., No teratogenic effects.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 General Toxicity Maternal: NOAEL: 0.025 mg/kg body weight
 Embryo-fetal toxicity.: NOAEL: 0.076 mg/kg body weight
 Result: No embryo-fetal toxicity., No teratogenic effects.

Reproductive toxicity - Assessment

: Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Halofuginone:

Target Organs : Blood
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

Repeated dose toxicity

Components:

Lactic acid:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks
Remarks : Based on data from similar materials

Species : Rat
LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

Halofuginone:

Species : Mouse
NOAEL : 0.07 mg/kg
LOAEL : 0.16 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Species : Rat
NOAEL : 0.13 mg/kg
LOAEL : 0.88 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Species : Dog
NOAEL : 0.067 mg/kg
LOAEL : 0.134 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Blood

Species : Dog
NOAEL : 0.075 mg/kg
LOAEL : 0.16 mg/kg
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Halofuginone:

General Information : No human information is available.

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
5.7	04/09/2022	845725-00017	Date of first issue: 08/26/2016

Inhalation	:	Remarks: May cause irritation of respiratory tract.
Skin contact	:	Remarks: May cause skin irritation and/or dermatitis. May cause sensitization by skin contact. Can be absorbed through skin.
Eye contact	:	Remarks: May irritate eyes.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lactic acid:

Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC50: > 10 - 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials

Halofuginone:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 1.8 mg/l Exposure time: 96 h Remarks: Based on data from similar materials LC50 (Cyprinus carpio (Carp)): 0.3 mg/l Exposure time: 72 h Remarks: Based on data from similar materials LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.12 mg/l Exposure time: 96 h Remarks: Based on data from similar materials
Toxicity to daphnia and other	:	EC50 (Daphnia magna (Water flea)): 0.02 mg/l

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

aquatic invertebrates Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50 (Chlorella pyrenoidosa): 46 mg/l
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Lactic acid:

Biodegradability : Result: Not readily biodegradable.
Remarks: Based on data from similar materials

Halofuginone:

Biodegradability : Result: Not readily biodegradable.

Bioaccumulative potential

Components:

Lactic acid:

Partition coefficient: n-octanol/water : log Pow: -0.62

Halofuginone:

Partition coefficient: n-octanol/water : log Pow: 1.18

Mobility in soil

Components:

Halofuginone:

Distribution among environmental compartments : log Koc: 3.87
Method: FDA 3.08

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

Halofuginone Formulation

Version 5.7 Revision Date: 04/09/2022 SDS Number: 845725-00017 Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Water	7732-18-5
Benzoic acid	65-85-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION**Further information**

SAFETY DATA SHEET



Halofuginone Formulation


Version
5.7

Revision Date:
04/09/2022

SDS Number:
845725-00017

Date of last issue: 03/26/2022
Date of first issue: 08/26/2016

NFPA 704:



HMIS® IV:

HEALTH	/	2
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
5.7	04/09/2022	845725-00017	Date of first issue: 08/26/2016

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8